Lonza

Today, we announced the launch of our Rapid Media Prototyping Service (RaMP), designed to help biopharmaceutical companies accelerate early bioprocess development with faster access to custom liquid and powder media. By providing non-GMP custom media in flexible batch sizes and with turnaround times of up to 10 working days, RaMP enables scientists to generate critical process data, make informed development decisions and keep programs moving forward. As part of Lonza's end-to-end custom media and buffer solutions offering, RaMP helps bridge early formulation work with future GMP manufacturing requirements, supporting a smoother path to scale-up and commercialization. Learn more: https://ow.ly/rtas50ZAkyS #Lonza #CDMO #Biotechnology #Bioprocessing

Geopolitical uncertainty is reshaping how biopharma companies approach sourcing, manufacturing and supply chain strategy. In Pharma's Almanac's July roundtable, Michael De Marco, Vice President of Commercial Development, Lonza Integrated Biologics, shared his perspective on how evolving tariffs, trade restrictions and regional policy developments are prompting drug developers to prioritize resilience alongside cost and speed. He discussed the growing importance of global manufacturing networks, regional expertise and trusted CDMO partnerships in helping companies navigate an increasingly complex operating environment. Read the full roundtable here: https://ow.ly/6V7850ZzKqQ #Lonza #CDMO #BiologicsManufacturing #SupplyChain

How can mAb programs reach the clinic in as little as six months without compromising quality or increasing development risk? In this expert Q&A, Lonza's James Berrie and Megan Mason discuss the platform strategies, integrated workflows, and regulatory considerations that enable accelerated DNA-to-IND timelines while maintaining confidence in product quality, consistency, and patient safety. 🔗 Read the article: https://ow.ly/kesP50Zzrb7 #Biologics #DrugDevelopment #DNAtoIND #Lonza

Watch the recording of our recent expert panel discussion to gain practical insights into comparability, regulatory considerations, and strategies for scaling AAV manufacturing. In this session, our experts discuss key considerations when transitioning from transient transfection to producer cell line technologies, including: ✅ Comparability approaches for platform transitions ✅ Factors influencing the need for bridging studies ✅ Regulatory considerations and risk mitigation ✅ Strategies to support scalable AAV manufacturing Whether you're evaluating producer cell line technologies or planning your next development milestones, this discussion offers practical guidance for navigating the transition with confidence. 🎥 Watch the recording: https://lnkd.in/ep7AyBPy #GeneTherapy #AAV #ProducerCellLines #CellLineDevelopment #BiologicsManufacturing #GeneTherapyManufacturing #Lonza

Lonza insight: End-to-End Bioconjugation What does it take to successfully advance a bioconjugate from early development to clinical and commercial manufacturing? Watch Sandro Holzer, Head of Development Bioconjugates, share how an integrated, end-to-end approach helps identify manufacturing risks early, accelerate CMC development, and build a scalable foundation for long-term success. From process development and technology transfer to clinical supply and commercial readiness, discover how bringing manufacturing expertise in early can help streamline the path to patients. Connect with our experts to learn more: https://ow.ly/zes250Zg7sW #Bioconjugates #ADCs #CMCDevelopment #CDMO #Biopharma

Watch Behnam Ahmadian Baghbaderani, Lonza VP and Global Head of Commercial and Program Management sit down with BioProcess International at BIO International to discuss the future of cell therapies. He discusses his optimism in the future of the field, explaining that constraints such as funding limitations are beginning to soften: “With the right focus and the right partnerships, and with commercial viability in mind, some of the funding challenges are easing up. Therapy developers are able to move toward their clinical and commercial launch in a more positive manner.” Catch the full interview for more on his reflection on industry trends from the perspective of a large CDMO. https://lnkd.in/exW_Qzyb

In this conversation with Fierce Biotech, Jaime Okray explains why bringing risk forward early helps teams generate the right data, choose the right molecule and move toward IND with greater confidence.  Drawing on Lonza’s work with approximately 1,500 small biotech companies and experience supporting 100 molecules on the market, the conversation makes a useful case for speed built on making informed choices.  Watch the interview below.

We're proud to share that Carrie Mason has been named to The Medicine Maker's 2026 Power List for Biopharma, recognizing individuals making a significant impact across the biopharmaceutical industry. This recognition highlights Carrie's work in advancing process analytical technologies (PAT) and next-generation biomanufacturing. Through her leadership of Lonza's PAT Center of Excellence, she is helping enable more adaptive, efficient and data-driven manufacturing processes. Congratulations, Carrie, on this well-deserved achievement. Read more about the 2026 Power List and Carrie's recognition: https://ow.ly/IRvH50ZxpqH #Lonza #Biotechnology #Biopharma #Innovation

As AAV gene therapy programs move toward larger indications, transient transfection can become harder to scale consistently and cost-effectively. In this fireside chat, Lonza experts discuss what it takes to transition from transient transfection to AAV producer cell lines, including how to think about comparability, bridging studies and regulatory risk. The discussion is relevant for CMC, regulatory affairs, process development, manufacturing and CDMO-facing teams working on AAV programs where future demand may challenge the limits of transient transfection. Watch to understand why timing matters, what attributes belong in a comparability package and when analytical data may or may not be enough to support a platform transition. 💡Key takeaways: producer cell line transitions can affect process control, impurity profiles, potency, full-empty ratio and cell line characterization; and earlier planning can reduce comparability and bridging challenges later. Watch the full discussion: https://lnkd.in/e-s6tfff

Join our upcoming webinar: “Before IND, know: How to overcome early development challenges before they impact your program”, to learn how early insights and strategic de-risking can help accelerate development, strengthen decision-making, and improve program outcomes. Featuring Dr. Yvette Stallwood, Head of Early Development Services, this session will explore how a proactive approach can support candidate selection, build investor and partner confidence, and help avoid costly development surprises. Learn from real-world case studies and gain practical insights you can apply to your own programs. 📅 Thursday, September 3, 2026 🕔 11:00am EDT | 5:00pm CEST 🎟️ Register now: https://ow.ly/IqaA50ZwqFu #Lonza #EarlyDevelopment #IND #CDMO